Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NovoCare Pharmacy vs Remi Meds

NovoCare Pharmacy
Graded #442

Higher grade

vs+6.800000000000004
Remi Meds
Graded #493

Lower grade

The verdict

NovoCare Pharmacy takes it — 55.2/100 to 48.4/100.

NovoCare Pharmacy grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Novo Nordisk's first-party direct-to-consumer pharmacy for branded Wegovy (semaglutide).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRemi Meds +10
24
34
Dose & formulationNovoCare Pharmacy +12
66
54
Clinical oversightNovoCare Pharmacy +20
74
54
Labs & monitoringNovoCare Pharmacy +1
51
50
FulfillmentNovoCare Pharmacy +23
76
53
Contract termsEven
55
55
NovoCare Pharmacy · left barRemi Meds · right bar

The numbers

MetricNovoCare PharmacyRemi Meds
WeighScore55.2/10048.4/100
GradeCC
Scorecard rank#442#493
Semaglutide$349/mo (2.4 mg dose, brand-name)$249/mo (0.25 mg dose, compounded)
TirzepatideNot disclosed$349/mo (2.25 mg dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
NovoCare Pharmacy

Graded #442 · C

Strengths

  • First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
  • $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
  • $349/mo standard self-pay is well below the ~$1,300/mo retail list price
  • Ships to all 50 states with no telehealth-platform middleman fees
  • Cold-chain logistics handled directly by Novo Nordisk

Where it loses points

  • Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
  • Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
  • No clinical support included — your own prescriber handles titration and side effects
  • Manufacturer-set pricing can change at any time
  • $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Remi Meds

Graded #493 · C

Strengths

  • Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
  • LegitScript verification badge on the homepage
  • Publishes 503A FDCA compliance language on the tirzepatide page
  • Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
  • Operating corporate entity disclosed (T-C Health Co)

Where it loses points

  • No named medical director, founder, or physician on any public page
  • States served not listed — 'nationwide' claim with no per-state detail
  • Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
  • Year founded and corporate history are opaque
  • Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard